New role for nuclear hormone receptors and coactivators in regulations of BRCA1-mediated DNA repair in breast cancer cell lines

Breast Cancer Research

Volumn 8, Issue 1, 2005, Pages

  Crowe, David L ^a   Lee, Matt K ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BROXURIDINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DOUBLE STRANDED DNA; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; HORMONE RECEPTOR; MUTANT PROTEIN; PLASMID DNA; RETINOIC ACID; RETINOIC ACID RECEPTOR;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL SURVIVAL; COMET ASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DAMAGE; DNA DETERMINATION; DNA REPAIR; GENETIC STABILITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NICK END LABELING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; WESTERN BLOTTING;

EID: 33750487170     PISSN: 1465542X     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1362     Document Type: Article

References (53)

1. Russo J, Hu YF, Yang X, Russo IH: Developmental, cellular, and molecular basis of human breast cancer. J Natl Cancer Inst Monogr 2000, 27:17-37.
2. Yang X, Lippman ME: BRCA1 and BRCA2 in breast cancer. Breast Cancer Res Treat 1999, 54:1-10.
3. Bertwistle D, Ashworth A: Functions of the BRCA1 and BRCA2 genes. Curr Opin Genet Dev 1998, 8:14-20.
4. Koonin EV, Altschul SF, Bork P: BRCA1 protein products: functional motifs. Nat Genet 1996, 13:266-268.
5. Callebaut I, Mornon JP: From BRCA1 to RAP1: a widespread BRCT module closely associated with DNA repair. FEBS Lett 1997, 400:25-30.
6. MacLachlan TK, Somasundaram K, Sgagias M, Shifman Y, Muschel RJ, Cowan KH, El-Deiry WS: BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression. J Biol Chem 2000, 275:2777-2785.
7. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T, Livingston DM: Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997, 88:265-275.
8. Kinzler KW, Vogelstein B: Gatekeepers and caretakers. Nature 1997, 386:761-763.
9. Brugarolas J, Jacks T: Double indemnity: p53, BRCA1, and cancer. Nat Med 1997, 3:721-722.
10. Husain A, He G, Venkatraman ES, Spriggs DR: BRCA1 upregulation is associated with repair mediated resistance to cis-diam-minedichloroplatinum(II). Cancer Res 1998, 58:1120-1123.
11. Hoeijmakers JHJ: Genome maintenance mechanisms for preventing cancer. Nature 2001, 411:366-374.
12. Takata M, Sasaki MS, Sonoda E, Morrison C, Hashimoto M, Utsumi H, Yamaguchi-Iwai Y, Shinohara A, Takeda S: Homologous recombination and non-homologous end joining pathways of DNA double strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J 1998, 17:5497-5508.
13. Zhou BB, Elledge SJ: The DNA damage response: putting checkpoints in perspective. Nature 2000, 408:433-439.
14. Khanna KK, Jackson SP: DNA double strand breaks: signaling, repair, and the cancer connection. Nat Genet 2001, 27:247-254.
15. Petrini JH: The Mre11 complex and ATM: collaborating to navigate S phase. Curr Opin Cell Biol 2000, 12:293-296.
16. Van Gent DC, Hoeijmakers JH, Kanaar R: Chromosomal stability and the DNA double stranded break connection. Nat Rev Genet 2001, 2:196-206.
17. Russo IH, Russo J: Role of hormones in cancer initiation and progression. J Mammary Gland Biol Neoplasia 1998, 3:49-61.
18. Huseby RA, Maloney TM, McGrath CM: Evidence for a direct growth stimulating effect of estradiol on human MCF-7 cells in vitro. Cancer Res 1984, 44:2654-2659.
19. Li Y, Hashimoto Y, Agadir A, Kagechika H, Zhang XK: Identification of a novel class of retinoic acid receptor β selective retinoids and their inhibitory effects on AP-1 activity and retinoic acid induced apoptosis in human breast cancer cells. J Biol Chem 1999, 274:15360-15366.
20. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, et al.: The nuclear receptor superfamily: the second decade. Cell 1995, 83:835-839.
21. Goodman RH, Smolik S: CBP/p300 in cell growth, transformation, and development. Genes Dev 2000, 14:1553-1577.
22. Chakravarti D, LaMorte VJ, Nelson MC, Nakajima T, Schulman IG, Juguilon H, Montminy M, Evans RM: Role of CBP/p300 in nuclear receptor signaling. Nature 1996, 383:99-103.
23. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y: The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996, 87:953-959.
24. Pao GM, Janknecht R, Ruffner H, Hunter T, Verma IM: CBP/p300 interact with and function as transcriptional coactivators of BRCA1. Proc Natl Acad Sci USA 2000, 97:1020-1025.
25. Gadal F, Starzec A, Bozic C, Pillot-Brochet C, Malinge S, Ozanne V, Vicenzi J, Buffat L, Perret G, Iris F, et al.: Integrative analysis of gene expression patterns predicts specific modulations of defined cell functions by estrogen and tamoxifen in MCF7 breast cancer cells. J Mol Endocrinol 2005, 34:61-75.
26. Vendrell JA, Bieche I, Desmetz C, Badia E, Tozlu S, Nguyen C, Nicolas JC, Lidereau R, Cohen PA: Molecular changes associated with the agonist activity of hydroxytamoxifen and the hyper-response to estradiol in hydroxytamoxifen resistant breast cancer cell lines. Endocr Relat Cancer 2005, 12:75-92.
27. Brem R, Hall J: XRCC1 is required for DNA single strand break repair in human cells. Nucleic Acids Res 2005, 33:2512-2520.
28. Willits I, Price L, Parry A, Tilby MJ, Ford D, Cholerton S, Pearson AD, Boddy AV: Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer 2005, 92:1626-1635.
29. Baldeyron C, Jacquemin E, Smith J, Jacquemont C, De Oliveira I, Gad S, Feunteun J, Stoppa-Lyonnet D, Papadopoulo D: A single mutated BRCA1 allele leads to impaired fidelity of double strand break end joining. Oncogene 2002, 21:1401-1410.
30. Reddy YV, Ding Q, Lees-Miller SP, Meek K, Ramsden DA: Non-homologous end joining requires that the DNA-PK complex undergo an autophosphorylation dependent rearrangement at DNA ends. J Biol Chem 2004, 279:39408-39413.
31. Chen Y, Lee WH, Chew HK: Emerging roles of BRCA1 in transcriptional regulation and DNA repair. J Cell Physiol 1999, 181:385-392.
32. Yager JD: Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr 2000, 27:67-73.
33. Mobley JA, Brueggemeier RW: Increasing the DNA damage threshold in breast cancer cells. Toxicol Appl Pharmacol 2002, 180:219-226.
34. Mobley JA, Brueggemeier RW: Estrogen receptor mediated regulation of oxidative stress and DNA damage in breast cancer. Carcinogenesis 2004, 25:3-9.
35. Bianco NR, Perry G, Smith MA, Templeton DJ, Montano MM: Functional implications of antiestrogen induction of quinine reductase: inhibition of estrogen induced deoxyribonucleic acid damage. Mol Endocrinol 2003, 17:1344-1355.
36. Reardon DB, Contessa JN, Mikkelsen RB, Valerie K, Amir C, Dent P, Schmidt-Ullrich RK: Dominant negative EGFR-CD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells. Oncogene 1999, 18:4756-4766.
37. Arnold SF, Obourn JD, Jaffe H, Notides AC: Phosphorylation of the human estrogen receptor by mitogen activated protein kinase and casein kinase II: consequence on DNA binding. J Steroid Biochem Mol Biol 1995, 55:163-172.
38. Rogatsky I, Trowbridge JM, Garabedian MJ: Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-cdk2 complex. J Biol Chem 1999, 274:22296-22302.
39. Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV, Cheng JQ: Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ER alpha) via interaction between ER alpha and PI3K. Cancer Res 2001, 61:5985-5991.
40. Valerie K, Povirk LF: Regulation and mechanisms of mammalian double strand break repair. Oncogene 2003, 22:5792-5812.
41. Chen JJ, Silver D, Cantor S, Livingston DM, Scully R: BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res 1999, 59(7 Suppl):1752s-1756s.
42. Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM: A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 2000, 10:886-895.
43. Coupier I, Baldeyron C, Rousseau A, Mosseri V, Pages-Berhouet S, Caux-Moncoutier V, Papadopoulo D, Stoppa-Lyonnet D: Fidelity of DNA double strand break repair in heterozygous cell lines harboring BRCA1 missense mutations. Oncogene 2004, 23:914-919.
44. Zhong Q, Chen CF, Chen PL, Lee WH: BRCA1 facilitates micro-homology mediated end joining of DNA double strand breaks. J Biol Chem 2002, 277:28641-28647.
45. Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos MR, Pestell RG, Yuan F, Auborn KJ, Goldberg ID, et al.: BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 1999, 284:1354-1356.
46. Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ, et al.: Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene 2001, 20:77-87.
47. Sourvinos G, Spandidos DA: Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 check-point in human sporadic breast tumors. Biochem Biophys Res Commun 1998, 245:75-80.
48. Fan S, Yuan R, Ma YX, Meng Q, Goldberg ID, Rosen EM: Mutant BRCA1 genes antagonize phenotype of wild type BRCA1. Oncogene 2001, 20:8215-8235.
49. Zhou C, Smith JL, Liu J: Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene 2003, 22:2396-2404.
50. 2 cell cycle arrest. Cancer Res 2004, 64:423-428.
51. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA: Estrogen receptor β inhibits 17β-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 2004, 101:1566-1571.
52. Cui JQ, Shao N, Chai Y, Wang H, Reddy ES, Rao VN: BRCA1 splice variants BRCA1a and BRCA1b associate with CBP co-activator. Oncol Rep 1998, 5:591-595.
53. Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ, et al.: p300 modulates the BRCA1 inhibition of estrogen receptor activity. Cancer Res 2002, 62:141-151.